Disability

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on…

2 years ago

ACMHCK and KDADS Select Netsmart to Propel Statewide Integration of CCBHCs in Kansas

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#BehavioralHealth--The Association of Community Mental Health Centers of Kansas (ACMHCK) has chosen Netsmart and its industry-leading Population…

2 years ago

Smoking Claims More Than 6,500 Lives, Costs Minnesota Over $9 Billion Annually 

New report commissioned by Blue Cross and Blue Shield of Minnesota exposes the ramifications of smoking on health and the…

2 years ago

Introducing Elument: Trailblazing the Future of Mental Health and Wellness

NASHVILLE, TN / ACCESSWIRE / January 16, 2024 / Elument,a trailblazer in mental health & wellness services, is proud to…

2 years ago

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s…

2 years ago

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")…

2 years ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old…

2 years ago

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…

2 years ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago